1. Home
  2. |Insights
  3. |DOJ Ends Use of SEPs in Resolving Violations of Environmental Law

DOJ Ends Use of SEPs in Resolving Violations of Environmental Law

Client Alert | 3 min read | 03.17.20

On March 12, 2020, the Environment and Natural Resources Division (ENRD) of the Department of Justice (DOJ) formally terminated its policy of permitting companies to perform environmentally beneficial projects – so-called “supplemental environmental projects” (SEPs) – in lieu of paying civil penalties for settlement of violations of federal environmental laws, according to a memo from ENRD Assistant Attorney General Jeffrey Bossert Clark. 

The prohibition on ENRD attorneys’ use of SEPs in environmental settlements is effective immediately. The new policy will not, however, affect prior settlements; in other words, settlements containing SEPs executed prior to the publication of the new policy remain valid. Notably, however, ongoing settlement negotiations may be affected: “I recognize the disruption could have on existing cases, particularly those in the final stage of negotiations where parties have long included SEPs as part of the proposed settlement.”

SEPs historically have been used to let parties agree to perform environmentally beneficial projects in exchange for lower fines. According to ENRD, however, the practice of using SEPs “has been controversial for decades,” and they “are as problematic as direct cash payments to third parties.” In his memo, Clark said that EPA’s SEP policy allowed defendants to reduce their civil penalties by up to 80% if they agreed to perform a SEP, i.e., in exchange for a $1 million SEP, civil penalties could be reduced by as much as $800,000. According to Clark, that arrangement would violate the Miscellaneous Receipts Act, a statute that prevents cash from legal settlements from being diverted from the Treasury to third parties. Furthermore, Clark rejected the argument that defendants who agree to perform a SEP should receive a lesser fine because the project reduces the severity of the offense: “The severity of the underlying offense is a historic fact by the time any enforcement action would even kick off,” Clark wrote. “SEPs are not time machines that can return to the point of the offense and soften the blow of an impending violation to the public or the environment.” While the stated justifications for this change in policy are clearly open to debate, there is no clear legal path to reversing this decision.

One area of uncertainty is the effect of the ENRD policy on EPA settlements that do not involve ENRD, i.e., settlements undertaken pursuant to EPA’s own administrative enforcement authority. EPA has used SEPs in its own administrative enforcement authority for decades, but the ENRD memo does not directly address this question. It states that it is “intended to govern the staff of the United States Department of Justice, Environment and Natural Resource Division, in their handling of enforcement actions.” Thus, by the terms of this memo, where EPA agrees to an administrative settlement containing a SEP and the settlement does not require ENRD approval, the settlement theoretically would be permissible. Whether EPA will continue to use SEPs in light of the new ENRD policy remains to be seen.

The memo also has other ambiguities complicating the ability of private parties to evaluate how it will be applied. For example, while early in the memo Clark states broadly that SEPs “will no longer be part of the suite of relief [ENRD] seeks in its cases (unless specifically authorized by Congress),” elsewhere the memo uses language (such as “should not”) indicating some potential for bending the new policy. But with no legal path to challenge this policy, private parties will either have to be in a wait-and-see mode to fully understand the contours of its implementation or resort to Congress for a legislative reversal of the new policy.

Insights

Client Alert | 4 min read | 04.18.24

Maryland and Colorado Say the Price Isn’t Right: State Drug Affordability Review Boards Seek Drug Upper Payment Limits

Following federal lawmakers’ initiative to lower prescription drug prices under the Inflation Reduction Act of 2022, several states have taken similar steps to limit certain drugs’ prices. Drug affordability for consumers is a top priority for federal and state lawmakers and regulators because it is a bipartisan issue that directly impacts consumers’ wallets. With negotiations between the federal government and drug manufacturers over 10 drugs’ prices for Medicare beneficiaries well underway under the Inflation Reduction Act, 11 states, including Maryland and Colorado, have created drug affordability review boards to more directly tackle rising prices for both brand and generic drugs.[1] And another 12 states have pending legislation to create these boards.[2] ...